Alphamab Oncology filed its monthly return to Hong Kong Exchanges and Clearing Limited for the period ended 31 July 2026. The filing shows no changes in either authorised or issued share capital during the month, and confirms compliance with the public-float requirement.

Authorised Share Capital • Remained at 25.10 billion ordinary shares with a par value of USD 0.000002, equivalent to total authorised capital of USD 50,200.

Issued and Treasury Shares • Outstanding shares (excluding treasury) stood at 968.51 million. • Treasury shares totalled 5.88 million. • Combined issued share count remained at 974.38 million, unchanged from the previous month. • The company affirmed that the public float exceeds the 25% threshold stipulated by HKEX rules.

Share Option Schemes • Pre-IPO Plan I: 9.21 million options outstanding; up to 2.31 million shares may be issued upon exercise. • Pre-IPO Plan II: 4.84 million options outstanding; up to 3.32 million shares may be issued. • Post-IPO Plan: 0.86 million options outstanding after 0.12 million options lapsed; 0.36 million shares remain issuable, with an overall mandate of up to 95.53 million shares under the refreshed limit approved on 12 June 2024. • No option grants, exercises, or cancellations were recorded in July, resulting in zero funds raised.

Other Equity Instruments • No movements in warrants, convertibles, share awards, or other share-issuance arrangements were reported. • Treasury shares were neither issued nor cancelled.

Overall, Alphamab Oncology’s capital structure remained static in July 2026, with minimal option-scheme activity and full compliance with HKEX listing requirements.